immunofluorescence reagents
  • Biotime's SARS-CoV-2 Antigen Test Obtains CE Mark for Self-testing
    Biotime's SARS-CoV-2 Antigen Test Obtains CE Mark for Self-testing March 16, 2022
    Biotime's SARS-CoV-2 Antigen test obtains CE mark for self-testing, the details are as follows: The SARS-CoV-2 Antigen Rapid Qualitative Test that has completed CE certification, this time is another effective tool for the company to actively support global anti-epidemic. It can be operated by individuals who collect the front nasal swab sample by themselves, and the result can be quickly obtained in 20-30 minutes, which is convenient for individuals and families to quickly detect Covid-19, well meets the needs of epidemic prevention and control at home in various countries, and further enriches the Biotime COVID-19 Solution. The company will fully support the cause of global COVID-19 prevention and control, and actively respond to the market demand for testing products in COVID-19.
    View More
  • The development of the boronate affinity chromatography and Biotime’s success
    The development of the boronate affinity chromatography and Biotime’s success March 14, 2022
    Boronate affinity chromatography (BAC) is a unique means for selective separation and enrichment of cis-diol-containing compounds. Cis-diol-containing biomolecules are an important class of compounds, including glycoproteins, glycopeptides, ribonucleosides, ribonucleotides, saccharides, and catecholamines. These biomolecules play essential roles in many life-related processes. Because cis-diol-containing biomolecules are important target molecules in current research frontiers such as proteomics, metabolomics, and glycomics, BAC and boronate affinity materials have gained rapid development and found increasing applications in recent decades. BAC is a unique mode of affinity chromatography, in which a boronic acid is used as the ligand for the selective isolation and enrichment of cis diol-containing compounds. The retention mechanism mainly relies on the pH-controlled reversible covalent interactions between cis-diol groups and the boronic acid ligand. As compared to other affinity chromatographic techniques, BAC exhibits several significant features, including broad-spectrum selectivity, reversible covalent binding, pH-controlled binding/release, and fast association/desorption kinetics. Owing to these merits, BAC is of great value in a variety of fields such as affinity separation, proteomic analysis, and metabolomics analysis.   HISTORICAL DEVELOPMENT The history of BAC can be simply divided into three different periods: early development period before 1970, approach-forming period 1970–2005, and new development period since 2006.   PRINCIPLE AND BINDING PH BAC principle relies on the reversible covalent reaction between cis-diol-containing compounds and boronic acid ligands. Figure 1 shows a general formula for the interaction between boronic acid and a cis diol-containing compound. When the surrounding pH is greater than the pKa value of the boronic acid, hydrolysis of the boronic acid occurs, resulting in a hybridization status change from trigonal coplanar shape to tetragonal boronate anion (from sp2 to sp3). The obtained tetragonal boronate anion can react with cis-diols and form five or six-membered cyclic esters. When the pH of the surrounding solution is switched to acidic, the boronic acid-cis-diol complex dissociates, because the binding strength between boronic acids in trigonal form and cis diol-containing compounds is very weak. Owing to the pH-controlled reversible covalent reaction, elution of captured analytes in BAC is very simple, just needing an acidic solution as the eluting buffer. Alternatively, the release of the captured analytes by the boronic acid ligands can be realized through adding excessive amounts of competing for cis-diol-containing molecules such as sorbitol into the loading buffer.   BORONATE AFFINITY CHROMATOGRAPHY Figure 1 Schematic diagram showing the interaction between boronic acids and cis-diol-containing compounds. INTERACTION MECHANISM AND SELECTIVITY MANIPULATION Selectivity is an esse...
    View More
  • Biotime Donated COVID-19 Test to Hong Kong
    Biotime Donated COVID-19 Test to Hong Kong March 11, 2022
    On March 10, Biotime donated 2 million of the SARS-COV-2 Antigen Rapid Qualitative Test Kits to Hong Kong. The increasing numbers of the Covid-19 in Hong Kong have been a big concern for the Chinese Government and its people. The Chinese Government has given full support to Hong Kong in its fight against the Covid-19. All sectors of the society and Hong Kong compatriots are helping each other and assisting Hong Kong in its fight against the Covid-19 in various ways. As a company that has long supported global anti-epidemic efforts through In Vitro Diagnostics, Biotime has actively responded to support Hong Kong in its fight against the COVID-19. We donated 12-million-yuan worth of epidemic prevention materials to Hong Kong. Biotime's Vice President of Operations, Jim Huang, presided over the donation ceremony. Mr. Huang said that as POCT developers, especially during the epidemic, we have a greater responsibility to share the worries and difficulties of our country and compatriots. Biotime COVID-19 antigen tests have played an outstanding role in the UK's epidemic prevention and controlling of the spread of Covid-19. Witnessing the Hong Kong epidemic increasing rapidly, Biotime hoped to play a significant role in Hong Kong's anti-epidemic efforts and assist Hong Kong to win the epidemic prevention and control the spread as soon as possible. ▲vice GM of Operation, Jim Huang Afterward, Biotime contacted Yi Zhiming, a member of the Hong Kong Legislative Council. Mr. Yi expressed his gratitude to the Xiamen Municipal Government and Biotime. He stated that the SARS-COV-2 Antigen Rapid Qualitative Test Kits, once they arrived, Covid-19 test kits will be delivered to the citizens quickly so that a protective wall can be built against the epidemic and protect the health of the Hong Kong citizens. Mr. Yi also mentioned working together will bring Hong Kong back to its former glory ▲ Connect with the senator of Legislative Council of the Hong Kong Special Administrative Region Yi Zhiming. ▲ Dong Zhonghong, Office of the Government of the Hong Kong Special Administrative Region in Fujian. Since Biotime was founded, it has committed itself actively to undertakings such as education, disaster relief, and fulfilling its social responsibility as a company and as well as a form of love to the world. As a result of the epidemic, Biotime has displayed "China's strength" in the prevention and control of epidemics across the globe. ▲ Donor Ceremony
    View More
  • How Productive is the D-Dimer for Chest Pains and Covid-19?
    How Productive is the D-Dimer for Chest Pains and Covid-19? March 02, 2022
    How Productive is the D-Dimer for Chest Pains and Covid-19?   D-dimers are cleavage products of fibrin that occur during plasmin-mediated fibrinolysis of blood clots. In the emergency department, D-dimer tests are broadly used as an excellent non-invasive triage biomarker in patients, which measurement represents a valuable and cost-effective tool in the differential diagnosis of acute chest pain including the main life-threatening entities: acute coronary syndrome, pulmonary embolism, and acute aortic syndrome. Whereas the diagnostic and prognostic values of D-dimer testing in acute coronary syndrome is of less priority, increases of D-dimers are frequently found in venous thromboembolism and acute aortic syndromes, especially acute aortic dissection.   Laboratory evaluation   D-dimer levels can be assessed by microplate enzyme-linked immunosorbent assay, enzyme-linked immunofluorescence assay, whole-blood cell agglutination, or latex agglutination tests. The sensitivity, specificity, and negative predictive value of D-dimer tests depend on the kind of used test, the cutoff value, and the kind of assumed disease. Cutoff levels are influenced by the kind of test used and may differ between different laboratories. D-dimer levels are associated with the amount of clotted blood. Highest levels are reached in massive venous thromboembolism and after cardiovascular arrest.   Influence of D-Dimers on ACS   Acute myocardial ischemia is caused by thrombotic occlusion of coronary arteries, implicating that D-dimer levels should be raised in focal coronary thrombosis. Whereas troponin is a highly sensitive and specific parameter for myocardial injury, elevation is measurable not until 3-4 hours after onset of symptoms. By contrast, D-dimer propose earlier rise than common markers of cardiac injury. It has been demonstrated that increased D-dimer levels may serve as an independent diagnostic marker for myocardial infarction with an increase in diagnostic sensitivity of the electrocardiogram and clinical history plus D-dimer.   Value of D-Dimer Measurement in PE   D-dimers have been shown to be highly sensitive in venous thromboembolism. Owing to the fact that deep vein thrombosis and pulmonary embolism often occur at the same time and up to 50% of patients with deep vein thrombosis have clinically inapparent pulmonary embolism, D-dimer levels can be used similarly in patients with deep vein thrombosis and pulmonary embolism. Therefore, the D-dimer test as a fast and cost-effective method is recommended in suspected pulmonary embolism.   D-Dimers in Aortic Dissection and other Aortic Syndromes   The term acute aortic syndrome includes different conditions ranging from an intramural hematoma to typical aortic dissection, together characterized by a disruption of the structural integrity of the aortic wall with subsequent initiation of coagulation. Apart from clinical presentation, imaging methods, and other biomark...
    View More
  • Adlai Nortye and Biotime Announce Technical and Commercial Partnership
    Adlai Nortye and Biotime Announce Technical and Commercial Partnership January 19, 2022
    Adlai Nortye Ltd. (“Adlai Nortye”) and Xiamen Biotime Biotechnology Co., Ltd. (“Biotime”) Announce Technical and Commercial Partnership on PD-L1 Inhibitors, Anti-hTNFR2 Antibody Products and Many Other Products Adlai Nortye Biopharma Co., Ltd. a global clinical-stage biopharmaceutical company focused on innovative oncology drugs, with R&D and global clinical operation centers in both China and the United States, has expanded its technical and commercial partnership with Xiamen Biotime Biotechnology Co., Ltd. a Hi-Tech enterprise that specialized in R&D, production, and sales of POCT in vitro diagnostic devices and reagents, and offer the industry’s most comprehensive in vitro diagnostics solutions to more than 60 countries and regions. The agreement aims to boost the development, production and commercialization of the PD-L1 inhibitors AN4005, anti-hTNFR2 antibody products and other products in Greater China and other regions of the world. Under the deal, the total amount of investment has reached several hundreds of millions of yuan which includes the down payment, the milestone payment that triggered by the milestone events and the royalties. The AN4005 Adlai Nortye developed is a drug candidates that made the fastest progress in clinical trials. It shows strong anti-tumour efficacy, good multibinding, high safety and meets clinical and commercial needs,in addition to that, it also shows great potential and might pioneer oral small-molecule inhibitor of PD-L1. AN3025 is a new humanized IgG1anti-hTNFR2 antibody which is in the early part of development of preclinical trial, it’s expected to enhance antitumor immune response which may help to achieved better tumour control and improve treatment. “Indigenous innovation is the core to Biotime, we just create a new business of innovative medicine, increase the research and development funding, take part in the innovative network and try to be a high-quality developer, innovative engineer to the industry.” said Yu Jianping, Executive Secretary of Biotime. “Adlai Nortye is a leading brand of innovative medicine, so this cooperation would be a win-win prospect.” “We are glad to come to an agreement with Biotime who has well-grounded research and technical capabilities, they continue to pursue innovation-driven development and highly value product research. Partnership is expected to begin the process profit-oriented, development of AN4005, AN3025 and other products across the globe. We are confident these products would benefit all the patient in the world and the cooperation would only accelerate the actions we are going to take.” said He Nanhai, Ph.D., Head of Adlai Nortye’s global R&D. About Biotime Established in April 2008, Xiamen Biotime is a Hi-tech enterprise that specialized in R&D, production, and sales of POCT in vitro diagnostic devices and reagents. Biotime has successfully settled the mature medical marketing channels during the past year...
    View More
  • National Day holiday
    National Day holiday September 30, 2021
    This is the official announcement of the National Day of the People's Republic of China. All our customers have been informed that due to the National Day holiday we will be closed on Friday 1st October and will resume normal business on Wednesday 8th October. We salute the founding of our country and the heroic warriors who gave their lives for this country. National Day holiday: October 1 to October 7, 2021 Reopen date: October 8, 2021 During this time, please feel free to call the office if you have any questions about your business. Congratulations and thanks to everyone who has contributed to the success of our business. Xiamen Biotechnology Co., Ltd. 30th September, 2021
    View More
  • Light-initiated Chemiluminescence Assay (LiCA)
    Light-initiated Chemiluminescence Assay (LiCA) September 29, 2021
    Light-initiated Chemiluminescence Assay (LICA) is derived from the luminescent oxygen channeling immunoassay (LOCI) with the desired features. Similar to the principle of LOCI, LICA is a homogenous bead-based technology in which the proximity of chemo beads and sensible ads (< 200 nm) generates light through CL. This homogeneous immunoassay method is capable of rapid, quantitative determination of a wide range of analytes--including high and very low concentrations of large and small molecules, free (unbound) drugs, DNA, and specific IgM. Light-initiated Chemiluminescence Assay is one of the emerging formats of immunoassay. More and more manufacturers set off to develop new products based on this new and innovative emerging technology because there are plenty of benefits of using it which include: Homogeneous High sensitivity High specificity High throughput Reproducibility Wide detection range Low sample volume Doesn’t require a washing step
    View More
  • Chemiluminescent Immunoassay
    Chemiluminescent Immunoassay September 02, 2021
    What is Chemiluminescent Immunoassay Chemiluminescent immunoassay (CLIA) is an immunoassay technique where the label, i.e. the true “indicator” of the analytic reaction, is a luminescent molecule. In general, luminescence is the emission of visible or near-visible radiation which is generated when an electron transition from an excited state to a ground state. The resultant potential energy in the atom gets released in the form of light. (Cinquanta, Fontana and Bizzaro, 2017) Chemiluminescent immunoassays offer one of the best solutions for the quantification of low concentrations of specific analytes from a complex mixture for in vitro diagnostic industry. They can also be used as diagnostic tools in medicine, as well as being used in several other different industries for various applications. (Lorne Laboratories, 2021) How Does Chemiluminescence Work Chemiluminescence immunoassay (CLIA) is an assay that combines the chemiluminescence techniques with immunochemical reactions. The assay format is similar to enzyme-linked immunoassays, usually based on heterogeneous assays where antibodies or antigens are immobilized on a solid phase but one of the components is conjugated with a chemiluminescent label. (Lorne Laboratories, 2021) (BrightTALK, 2021) CLIA utilizes chemical probes which could generate light emission through a chemical reactions to label the antibody. (Creative-diagnostics, 2021) The Benefits of Chemiluminescence Immunoassay In recent years, CLIA has gained increasing attention in different fields, including life science, clinical diagnosis, environmental monitoring, food safety, and pharmaceutical analysis because there are benefits of using chemiluminescence such as: ultra-sensitive good specificity wide range of applications simple equipment wide linear range easier in operation and design can detect small amounts of the biological molecule does not require long incubations and the addition of stopping reagents (Creative-diagnostics, 2021) Key Types of Chemiluminescent Immunoassay Methods Chemiluminescent methods that have been commonly seen are direct - using luminophore markers, indirect—using enzyme markers, or electrogenerated – typically nanomaterials based. (Cinquanta, Fontana and Bizzaro, 2017) (Ju, Lai and Yan, 2017) Indirect CLIA, using enzyme markers This common CLIA method involves an enzyme, typically horseradish peroxidase (HRP) or alkaline phosphatase (AP), conjugated to a secondary antibody. This HRP– or AP–secondary antibody complex then catalyzes the conversion of chemiluminescent substrate, luminol and CSPD reagent respectively. These substrates, when oxidized, provide an easy means of signal detection and quantification due to prolonged signal emission. (Shimadzu, 2021) Direct CLIA, using luminophore markers This method commonly uses acridinium esters as luminophores conjugated directly to the primary monoclonal antibody to generate a signal. Acridinium esters are highly specific labels that spontaneously oxidiz...
    View More
First 1 2 3 4 5 Last
[  A total of  5  pages]
Leave A Message

Leave A Message

    Please provide us with the information below, and we'll contact you as soon as possible.